Monte Rosa Therapeutics, Inc.
$8.64-$0.27 (-3.0%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.5B
- P/E
- -38.0x
- EV / EBITDA
- -30.0x
- Revenue
- $123.7M
- Net margin
- -31.2%
- ROCE
- -14.1%
Price chart
Technical chartScreen technicals →-36.1% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -23.9%
- 3M
- -41.5%
- 6M
- -53.7%
- 1Y
- -36.1%
- 5Y
- -55.9%
52-week range
Day change -$0.27 (-3.0%) from $9 to $9 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in GLUE, bought on each weekday since 2021.
News & filings
What Monte Rosa Therapeutics filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 38.6 million US dollars in fiscal 2025.
Strengths (1)
- Revenue grew 63.5% in fiscal 2025.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
Read moreShow less
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 65.5M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.5B
- P/E
- -38.0x
- P/B
- 6.3x
- EV / EBITDA
- -30.0x
- EV / Sales
- 11.1x
- P/S
- 11.9x
- 52-week high
- $25.31
- 52-week low
- $8.64
Profitability
- Operating margin
- -43.8%
- Net margin
- -31.2%
- EBITDA margin
- -37.1%
- ROE
- -16.6%
- ROCE
- -14.1%
- ROIC
- -30.1%
- ROA
- -8.6%
- Asset turnover
- 0.28
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $123.7M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 63.5%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -46.9%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$27.5M
Solvency
- Current ratio
- 6.12
- Debt / Equity
- 0.17
- Debt / Assets
- 0.09
- CFO / Net profit
- 0.59
- Cash / Market cap
- 8.9%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $123.7M |
| Gross profit | $123.7M |
| Operating expenses | $177.9M |
| Research and development | $141.5M |
| Selling, general and administrative | $36.4M |
| Operating income | -$54.2M |
| Interest and other | $14.5M |
| Pretax income | -$39.7M |
| Tax and other | -$1.1M |
| Net income | -$38.6M |
Revenue and net profit
Revenue grew 63.5% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $0.00 | -$108.5M |
| FY2023 | $0.00 | -$135.4M |
| FY2024 | $75.6M | -$72.7M |
| FY2025 | $123.7M | -$38.6M |
Cash flows
FY2025: -$22.8M from operations, -$27.5M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$92.5M | -$105.4M |
| FY2023 | -$43.8M | -$62.8M |
| FY2024 | $42.0M | $38.0M |
| FY2025 | -$22.8M | -$27.5M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $123.7M+63.5%1Y
- EBITDA
- -$45.9M
- Net profit
- -$38.6M
- Cash from operations
- -$22.8M-154.3%1Y
- Free cash flow
- -$27.5M-172.3%1Y
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $123.7M | -$45.9M | -$38.6M | -$27.5M | -16.6% | +63.5% | -46.9% |
Monthly returns
Month-by-month returns of GLUE across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $448.7M |
| Current assets | $393.2M |
| Non-current assets | $55.5M |
| Liabilities | $215.6M |
| Current liabilities | $64.2M |
| Non-current liabilities | $151.4M |
| Equity | $233.1M |
| Paid-in capital | $714.1M |
| Retained earnings | -$477.2M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; GLUE highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): MBX Biosciences, Inc., Maze Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc.GLUEthis company | $1.5B | -38.0x | 6.3x | -16.6% | -30.0x |
| AnaptysBio, Inc.ANAB | $1.5B | — | 40.4x | -35.6% | 17.4x |
| STAAR Surgical CompanySTAA | $1.5B | -18.5x | 4.3x | -23.4% | -36.9x |
| Perrigo Company plcPRGO | $1.5B | -1.0x | 0.5x | -48.6% | -5.7x |
| NeoGenomics, Inc.NEO | $1.5B | -13.6x | 1.8x | -12.9% | -44.5x |
| MBX Biosciences, Inc.MBX | $1.5B | -16.9x | 4.0x | -23.6% | -14.3x |
| Aveanna Healthcare Holdings Inc.AVAH | $1.4B | 6.4x | 7.4x | 115.3% | 10.3x |
| Septerna, Inc.SEPN | $1.4B | -28.9x | 3.7x | -12.8% | -16.6x |
| Maze Therapeutics, Inc.MAZE | $1.4B | -10.7x | 4.0x | -36.9% | -8.8x |
| Peer median | — | -13.6x | 4.0x | -23.5% | -11.6x |
Year-to-date ROI
GLUE since 1 January, against earlier years.
Historical volatility
GLUE's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2024 | -107.3% |
| FY2025 | -43.8% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $123.7M |
| Operating expensesOperating Expense | $177.9M |
| Research and developmentResearch And Development | $141.5M |
| Selling, general and administrativeSelling General And Administration | $36.4M |
| Total expensesTotal Expenses | $177.9M |
| Operating incomeOperating Income | -$54.2M |
| Interest and other | |
| Pretax incomePretax Income | -$39.7M |
| TaxTax Provision | -$1.1M |
| Net incomeNet Income | -$38.6M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $448.7M |
| Current assetsCurrent Assets | $393.2M |
| Non-current assetsTotal Non Current Assets | $55.5M |
| LiabilitiesTotal Liabilities Net Minority Interest | $215.6M |
| Current liabilitiesCurrent Liabilities | $64.2M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $151.4M |
| EquityTotal Equity Gross Minority Interest | $233.1M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$22.8M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$22.8M |
| Net income, continuing operationsNet Income From Continuing Operations | -$38.6M |
| Depreciation and amortisationDepreciation And Amortization | $8.4M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $8.4M |
| Depreciation | $8.4M |
| Amortization of securitiesAmortization Of Securities | -$2.1M |
| Stock-based compensationStock Based Compensation | $18.9M |
| Operating gains and lossesOperating Gains Losses | -$60.0k |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | -$60.0k |
| Change in working capitalChange In Working Capital | -$9.2M |
| Other non-cash itemsOther Non Cash Items | — |
| Investing cash flowInvesting Cash Flow | -$101.8M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$101.8M |
| Capital expenditureCapital Expenditure | -$4.7M |
| Purchase of PP&EPurchase Of PPE | -$4.7M |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$4.7M |
| Purchase of investmentsPurchase Of Investment | -$376.7M |
| Sale of investmentsSale Of Investment | $279.5M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$97.1M |
| Financing cash flowFinancing Cash Flow | $30.4M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $30.4M |
| Shares issuedIssuance Of Capital Stock | $24.3M |
| Common stock issuedCommon Stock Issuance | $24.3M |
| Net common stock issuedNet Common Stock Issuance | $23.9M |
| Common stock repurchasedCommon Stock Payments | -$360.0k |
| Share buybacksRepurchase Of Capital Stock | -$360.0k |
| Stock options exercisedProceeds From Stock Option Exercised | $6.5M |
| Preferred stock issuancePreferred Stock Issuance | — |
| Net preferred stock issuanceNet Preferred Stock Issuance | — |
| Other financing chargesNet Other Financing Charges | — |
| Change in cashChanges In Cash | -$94.3M |
| Cash at the start of the yearBeginning Cash Position | $229.1M |
| Cash at the end of the yearEnd Cash Position | $134.8M |
| Free cash flowFree Cash Flow | -$27.5M |
Learn while you research
Academy chapters picked for Monte Rosa Therapeutics, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing64% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read